|本期目录/Table of Contents|

[1]郑贝贝,朱 诺,杨 玖.EGFR-TKI联合胸部三维放疗治疗Ⅳ期非小细胞肺癌疗效分析[J].中华肺部疾病杂志,2021,(04):511-513.[doi:10.3877/cma.j.issn.1674-6902.2021.04.030]
点击复制

EGFR-TKI联合胸部三维放疗治疗Ⅳ期非小细胞肺癌疗效分析(PDF)

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2021年04期
页码:
511-513
栏目:
短篇论著
出版日期:
2021-08-20

文章信息/Info

Title:
-
作者:
郑贝贝; 朱 诺; 杨 玖
210000 南京,南京市胸科医院
Author(s):
-
关键词:
非小细胞肺癌;  放疗;  EGFR-TKI
Keywords:
-
分类号:
R734.2
DOI:
10.3877/cma.j.issn.1674-6902.2021.04.030
摘要:
-
Abstract:
-

参考文献/References:

1 Brown S, Banfill K, Aznar MC, et al. The evolving role of radiotherapy in non-small cell lung cancer[J]. Br J Radiol, 2019, 92(1104): 201-204.
2 Burdett S, Rydzewska L, Tierney J, et al. Postoperative radiotherapy for non-small cell lung cancer[J]. Cochrane Database Syst Rev, 2016, 10(10): D2142.
3 Brooks ED, Verma V, Senan S, et al. Salvage therapy for locoregional recurrence after stereotactic ablative radiotherapy for early-stage NSCLC[J]. J Thorac Oncol, 2020, 15(2): 176-189.
4 Ko EC, Raben D, Formenti SC. The integration of radiotherapy with immunotherapy for the treatment of non-small cell lung cancer[J]. Clin Cancer Res, 2018, 24(23): 5792-5806.
5 Iyengar P, Wardak Z, Gerber DE, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: A phase 2 randomized clinical trial[J]. JAMA Oncol, 2018, 4(1): e173-e175.
6 Gelatti A, Drilon A, Santini FC. Optimizing the sequencing of tyrosine kinase inhibitors(TKIs)in epidermal growth factor receptor(EGFR)mutation-positive non-small cell lung cancer(NSCLC)[J]. Lung Cancer, 2019, 137(4): 113-122.
7 Wu SG, Shih JY. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer[J]. Mol Cancer, 2018, 17(1): 38-39.
8 Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer[J]. N Engl J Med, 2018, 378(2): 113-125.
9 Cheng H, Li XJ, Wang XJ, et al. A meta-analysis of adjuvant EGFR-TKIs for patients with resected non-small cell lung cancer[J]. Lung Cancer, 2019, 137(6): 7-13.
10 Jiang T, Zhang Y, Li X, et al. EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases[J]. Eur J Cancer, 2019, 121(1): 98-108.
11 Ballard P, Yates JW, Yang Z, et al. Preclinical Comparison of osimertinib with other EGFR-TKIs in EGFR-Mutant NSCLC Brain metastases models, and early evidence of clinical brain metastases activity[J]. Clin Cancer Res, 2016, 22(20): 5130-5140.
12 中华医学会, 中华医学会肿瘤学分会, 中华医学会杂志社. 中华医学会肺癌临床诊疗指南(2019版)[J]. 中华肿瘤杂志, 2020, 42(4): 257-287.
13 邓小茜, 戈 伟. SBRT与IMRT治疗早期非小细胞肺癌的疗效与生存情况分析[J]. 武汉大学学报(医学版), 2020, 41(5): 754-757.
14 Boyd MR, Paull KD. Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen[J]. Drug Dev Res, 2010, 34(2): 91-109.
15 陈宏达, 郑荣寿, 王 乐, 等. 2019年中国肿瘤流行病学研究进展[J]. 中华疾病控制杂志, 2020, 24(4): 373-379.
16 Takeda M, Nakagawa K. First- and second-generation EGFR-TKIs are all replaced to osimertinib in chemo-naive EGFR mutation-positive non-small cell lung cancer?[J]. Int J Mol Sci, 2019, 20(1): 402-403.
17 Hsu PC, Jablons DM, Yang CT, et al. Epidermal growth factor receptor(EGFR)pathway, yes-associated protein(YAP)and the regulation of programmed death-ligand 1(PD-L1)in non-small cell lung cancer(NSCLC)[J]. Int J Mol Sci, 2019, 20(15): 214-216.
18 Yoneda K, Imanishi N, Ichiki Y, et al. Treatment of non-small cell lung cancer with EGFR-mutations[J]. J UOEH, 2019, 41(2): 153-163.
19 Russo A, Franchina T, Ricciardi G, et al. Heterogeneous responses to epidermal growth factor receptor(EGFR)tyrosine kinase inhibitors(TKIs)in patients with uncommon EGFR mutations: new insights and future perspectives in this complex clinical scenario[J]. Int J Mol Sci, 2019, 20(6): 175-177.
20 Recondo G, Facchinetti F, Olaussen KA, et al. Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?[J]. Nat Rev Clin Oncol, 2018, 15(11): 694-708.
21 Castellanos E, Feld E, Horn L. Driven by mutations: The predictive value of mutation subtype in EGFR-mutated non-small cell lung cancer[J]. J Thorac Oncol, 2017, 12(4): 612-623.
22 杨 玖, 洪 梅, 刘志远, 等. 放疗联合EGFR-TKI靶向治疗对Ⅳ期非小细胞肺癌患者血清肿瘤标记物及疗效的影响[J]. 河北医学, 2020, 26(1): 4-8.
23 Saida Y, Watanabe S, Abe T, et al. Efficacy of EGFR-TKIs with or without upfront brain radiotherapy for EGFR-mutant NSCLC patients with central nervous system metastases[J]. Thorac Cancer, 2019, 10(11): 2106-2116.
24 Tan CS, Kumarakulasinghe NB, Huang YQ, et al. Third generation EGFR TKIs: current data and future directions[J]. Mol Cancer, 2018, 17(1): 29-30.
25 Shetty V, Babu S. Management of CNS metastases in patients with EGFR mutation-positive NSCLC[J]. Indian J Cancer, 2019, 56(9): S31-S37.
26 Baraibar I, Mezquita L, Gil-Bazo I, et al. Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC[J]. Crit Rev Oncol Hematol, 2020, 148(3): 102-104.
27 Lin A, Wei T, Meng H, et al. Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer(NSCLC)with EGFR mutations[J]. Mol Cancer, 2019, 18(1): 139-141.
28 吴海波, 刘若男, 高 敏, 等. 非小细胞肺癌患者血清肿瘤异常蛋白的表达与化疗疗效的相关性[J]. 临床肺科杂志, 2020, 25(9): 1395-1399.
29 Rebuzzi SE, Alfieri R, La Monica S, et al. Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: Review of the literature and future perspectives [J]. Crit Rev Oncol Hematol, 2020, 146(9): 102-104.
30 聂志凤. EGFR-TKI单药或联合放疗治疗非小细胞肺癌肺毒性研究进展[J]. 中国肿瘤临床, 2017, 44(11): 558-561.

备注/Memo

备注/Memo:
通信作者: 郑贝贝, Email: dr13775955386@163.com
更新日期/Last Update: 2021-08-20